LNAI revenueQ4 2026$31.1K
- QoQ
- +48.3%
LNAI revenue was $31.1K in fiscal Q4 2026 (ended Jun 30, 2026), up 48.3% from the prior quarter. For the full fiscal 2026 it was $52.0K.
Lunai Bioworks Inc. (LNAI) financials
For fiscal 2026 (ended Jun 30, 2026), Lunai Bioworks Inc. reported $52.0K of revenue and -$3.56M of net income.
- Revenue, FY2026
- $52.0K
- Net income, FY2026
- -$3.56M
- Net margin
- -6852.0%
- Free cash flow, FY2026
- -$5.29M
- EPS, diluted, FY2026
- -$1.06
- Cash
- $1.71M
- Total debt
- $388.3K
- P/S
- 28.53
- Market cap
- $1.5M
FY2017FY2026
FY2018FY2026
LNAI revenue and earnings growth
LNAI net incomeQ4 2026-$2.01M
LNAI net income was -$2.01M in fiscal Q4 2026 (ended Jun 30, 2026), compared with -$126.73M a year earlier. For the full fiscal 2026 it was -$3.56M, compared with -$178.01M in fiscal 2025.
LNAI EPSFY2026-$1.06
LNAI diluted EPS was -$1.06 for fiscal 2026 (ended Jun 30, 2026).
LNAI free cash flowQ4 2026-$1.84M
LNAI free cash flow was -$1.84M in fiscal Q4 2026 (ended Jun 30, 2026). For the full fiscal 2026 it was -$5.29M.
Income statement
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.0K | - | - | - | - | - | - | - | - | - |
| Research and development | $24.5K | $537.4K | $2.71M | $4.17M | $8.37M | $15.72M | $4.69M | $2.50M | $617.0K | $62.8K |
| Selling, general and admin | $7.80M | $17.88M | $24.56M | $15.32M | $14.33M | $7.56M | $7.12M | $8.42M | $3.90M | $933.8K |
| Operating income | -$8.70M | -$188.97M | -$81.64M | -$38.56M | -$116.08M | -$23.40M | -$11.92M | -$10.99M | -$5.33M | -$2.40M |
| Interest expense | $235.1K | $725.7K | $1.01M | $580.3K | $372.8K | $379.6K | $104.3K | $43 | $143.3K | - |
| Pre-tax income | - | - | - | -$39.68M | -$113.43M | -$26.85M | -$11.42M | -$18.02M | -$6.42M | -$2.21M |
| Income tax | $1.4K | $1.5K | $0 | - | $34 | -$125.3K | - | - | -$111.7K | -$64.9K |
| Net income | -$3.56M | -$178.01M | -$88.43M | -$39.68M | -$113.43M | -$26.72M | -$11.42M | -$18.02M | -$6.31M | -$2.14M |
| EPS, basic | -$1.06 | -$86.27 | -$9.10 | -$7.10 | -$21.60 | -$5.70 | -$2.50 | -$4.80 | -$2.90 | -$1.70 |
| EPS, diluted | -$1.06 | -$86.27 | -$9.10 | -$7.10 | -$21.60 | -$5.70 | -$2.50 | -$4.80 | -$2.90 | -$1.70 |
| Diluted shares | 3.4M | 2.1M | 9.8M | 5.6M | 5.3M | 4.7M | 4.6M | 3.8M | 2.2M | 1.2M |
Balance sheet
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.71M | $92.7K | $220.5K | $1.87M | $9.17M | $20.66M | $8.70M | $12.28M | $15.60M | $3.94M |
| Current assets | $2.04M | $1.05M | $2.00M | $2.57M | $9.57M | $20.90M | $8.94M | $12.49M | $15.76M | $4.20M |
| Goodwill | $5.96M | $5.96M | $159.33M | $11.64M | $11.64M | $11.64M | $11.64M | $11.64M | $11.64M | - |
| Total assets | $9.94M | $8.23M | $163.13M | $58.30M | $84.63M | $189.61M | $178.10M | $179.88M | $182.50M | $4.52M |
| Current liabilities | $18.91M | $29.16M | $30.31M | $11.02M | $6.45M | $1.89M | $1.33M | $1.11M | $873.7K | $2.99M |
| Long-term debt | - | - | - | $0 | $1.20M | $1.20M | $1.20M | - | - | - |
| Total debt | $388.3K | $3.58M | - | $0 | $1.20M | $1.20M | $1.20M | - | - | - |
| Total liabilities | $18.97M | $29.58M | $31.15M | $11.80M | $12.01M | $14.94M | $11.83M | $6.78M | $23.76M | $2.99M |
| Shareholders' equity | -$9.02M | -$21.35M | $131.98M | $46.50M | $72.62M | $174.66M | $166.27M | $173.10M | $158.74M | $1.53M |
Cash flow
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.29M | -$7.87M | -$10.97M | -$11.77M | -$15.73M | -$20.61M | -$10.46M | -$8.51M | -$4.34M | -$1.18M |
| Capital expenditures | $1.2K | - | $70.4K | $29.8K | $5.2K | $48.9K | $184.5K | $716.7K | $30.0K | - |
| Free cash flow | -$5.29M | - | -$11.04M | -$11.80M | -$15.74M | -$20.66M | -$10.64M | -$9.22M | -$4.37M | - |
| Investing cash flow | $543.5K | -$500.0K | -$1.26M | -$29.8K | -$5.2K | -$48.9K | -$184.5K | -$716.7K | -$575.7K | -$196.1K |
| Financing cash flow | $6.39M | $8.38M | $10.52M | $4.52M | $4.25M | $32.60M | $7.20M | $6.02M | $16.71M | $5.51M |
| Stock-based compensation | $630.4K | $3.31M | $4.67M | $3.54M | $5.24M | $1.30M | $884.7K | $2.12M | $63.7K | - |
| Depreciation and amortization | $93.5K | $129.1K | $121.9K | $113.5K | $123.6K | $123.5K | $108.6K | $71.7K | $18.5K | $14.5K |
Key ratios
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -16729.4% | - | - | - | - | - | - | - | - | - |
| Net margin | -6852.0% | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | -10173.6% | - | - | - | - | - | - | - | - | - |
| Return on equity | - | - | -67.0% | -85.3% | -156.2% | -15.3% | -6.9% | -10.4% | -4.0% | -139.8% |
| Return on assets | -35.8% | -2162.7% | -54.2% | -68.1% | -134.0% | -14.1% | -6.4% | -10.0% | -3.5% | -47.4% |
| Current ratio | 0.11 | 0.04 | 0.07 | 0.23 | 1.48 | 11.08 | 6.70 | 11.25 | 18.04 | 1.40 |
| Debt to equity | - | - | - | 0.00 | 0.02 | 0.01 | 0.01 | - | - | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $31.1K | $20.9K | - | - | - | - | - | - | - | - | - | $61.2K |
| Gross profit | - | $20.9K | - | - | - | - | - | - | - | - | - | - |
| Research and development | -$61.7K | $15.9K | $45.9K | $24.4K | - | - | $161.1K | $390.2K | $434.5K | $1.09M | $620.5K | $566.6K |
| Selling, general and admin | $2.20M | $1.42M | $1.77M | $2.41M | $4.00M | $4.22M | $4.35M | $5.30M | $5.00M | $7.65M | $3.62M | $8.29M |
| Operating income | -$2.14M | -$1.48M | -$1.82M | -$3.31M | -$126.92M | -$4.16M | -$4.55M | -$53.34M | -$17.10M | -$51.38M | -$4.27M | -$8.88M |
| Interest expense | -$116.9K | $108.1K | $121.5K | $122.4K | $188.0K | $188.7K | $98.9K | $250.1K | $253.3K | $303.8K | $275.0K | $179.3K |
| Pre-tax income | - | - | - | - | - | - | - | - | - | - | - | -$9.18M |
| Net income | -$2.01M | -$2.57M | -$1.80M | $2.82M | -$126.73M | $189.2K | -$7.25M | -$44.21M | -$15.73M | -$58.99M | -$4.53M | -$9.18M |
| EPS, basic | - | -$0.10 | -$0.08 | $1.30 | - | $0.00 | -$0.45 | -$27.60 | - | -$5.40 | -$0.70 | -$1.40 |
| EPS, diluted | - | -$0.10 | -$0.08 | $1.30 | - | $0.00 | -$0.45 | -$27.60 | - | -$5.40 | -$0.70 | -$1.40 |
| Diluted shares | - | 25.0M | 23.5M | 2.3M | - | 16.4M | 16.2M | 1.6M | - | 10.9M | 6.6M | 6.4M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.71M | $3.16M | $491.6K | $624.8K | $92.7K | $923.0K | $311.8K | $220.6K | $220.5K | $312.7K | $244.0K | $523.5K |
| Receivables | - | - | - | - | - | $964.4K | - | - | - | - | $1.07M | $1.06M |
| Current assets | $2.04M | $3.73M | $514.5K | $800.4K | $1.05M | $3.67M | $1.71M | $1.95M | $2.00M | $1.22M | $2.40M | $1.91M |
| Goodwill | $5.96M | $5.96M | $5.96M | $5.96M | $5.96M | $112.64M | $108.00M | $118.17M | $159.33M | $164.19M | $11.64M | $11.64M |
| Total assets | $9.94M | $9.86M | $6.67M | $6.96M | $8.23M | $117.73M | $111.34M | $121.83M | $163.13M | $178.09M | $58.02M | $57.56M |
| Current liabilities | $18.91M | $19.28M | $20.00M | $19.72M | $29.16M | $28.84M | $28.61M | $23.04M | $30.31M | $20.87M | $13.76M | $10.10M |
| Long-term debt | - | - | $978.5K | $938.5K | - | - | - | - | - | - | - | - |
| Total debt | $388.3K | - | $978.5K | $938.5K | $3.58M | - | - | - | - | - | - | - |
| Total liabilities | $18.97M | $19.41M | $20.22M | $20.00M | $29.58M | $29.34M | $29.28M | $23.75M | $31.15M | $43.68M | $14.42M | $10.82M |
| Shareholders' equity | -$9.02M | -$9.55M | -$13.55M | -$13.04M | -$21.35M | $88.39M | $82.06M | $98.09M | $131.98M | $134.41M | $43.60M | $46.75M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.84M | -$1.03M | -$1.07M | -$1.35M | -$1.81M | -$1.49M | -$2.56M | -$2.02M | -$2.41M | -$2.63M | -$3.15M | -$2.78M |
| Capital expenditures | $0 | $0 | - | - | - | - | - | - | $23.6K | $5.3K | - | - |
| Free cash flow | -$1.84M | -$1.03M | - | - | - | - | - | - | -$2.44M | -$2.64M | - | - |
| Investing cash flow | $0 | $0 | -$1.2K | $544.7K | $964.4K | - | - | $0 | -$53.4K | -$91.6K | -$57.3K | -$1.06M |
| Financing cash flow | $394.6K | $3.70M | $950.0K | $1.34M | $178.4K | $3.58M | $2.59M | $2.03M | $2.47M | $2.64M | $2.85M | $2.56M |
| Stock-based compensation | $151.3K | $169.0K | $128.8K | $181.3K | $897.8K | $1.50M | $558.6K | $357.6K | $828.5K | $1.86M | $999.2K | $983.8K |
| Depreciation and amortization | $29.7K | $11.0K | $11.3K | $41.5K | $38.4K | $32.0K | $32.1K | $32.4K | $31.1K | $30.3K | $33.2K | $27.3K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | - | - | - | - | - | -57.6% |
| Gross margin | - | 100.0% | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -6888.6% | -7054.1% | - | - | - | - | - | - | - | - | - | -14511.1% |
| Net margin | -6475.7% | -12278.6% | - | - | - | - | - | - | - | - | - | -14986.2% |
| Free cash flow margin | -5929.2% | -4903.3% | - | - | - | - | - | - | - | - | - | - |
| Current ratio | 0.11 | 0.19 | 0.03 | 0.04 | 0.04 | 0.13 | 0.06 | 0.08 | 0.07 | 0.06 | 0.17 | 0.19 |
Source: XBRL data Lunai Bioworks Inc. files with the SEC, latest filing dated Oct 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Feb 17, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
LNAI peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| LNAI | $52.0K | - | -$3.56M | -6852.0% | $1.5M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.03B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $521.41B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $362.83B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $305.91B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $287.63B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $189.28B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $181.94B |
LNAI FAQ
7 questionsWhat is LNAI revenue?
Lunai Bioworks Inc. (LNAI) reported $52.0K of revenue for fiscal 2026 (ended Jun 30, 2026).Is LNAI profitable?
No. Lunai Bioworks Inc. reported a net loss of $3.56M for fiscal 2026 (ended Jun 30, 2026).How much cash and debt does LNAI have?
Lunai Bioworks Inc. reported $1.71M in cash and cash equivalents and $388.3K of debt on its most recent balance sheet in SEC filings.What is LNAI free cash flow?
Lunai Bioworks Inc. generated -$5.29M of free cash flow for fiscal 2026 (ended Jun 30, 2026), which is operating cash flow of -$5.29M less capital expenditures.What is LNAI earnings per share?
Diluted earnings per share were -$1.06 for fiscal 2026 (ended Jun 30, 2026), from SEC filings, restated for any stock split those filings show.When did LNAI last report financial results?
The latest statements here come from Lunai Bioworks Inc.'s 10-K filed on Oct 13, 2026, covering the period ended Jun 30, 2026.Where does this LNAI financial data come from?
Quantisnow builds these statements from the structured XBRL data Lunai Bioworks Inc. files with the SEC. It is provided for information only and is not investment advice.